WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Primary Sclerosing Cholangitis - Pipeline Review, H1 2018”
Primary Sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Bile ducts are refer to as tubes which carry bile into the upper part of the bowel. The bile also enables the body to absorb vitamins A, D, E and K from our diet.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Primary Sclerosing Cholangitis Industry Major Highlights:
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Primary Sclerosing Cholangitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Outlook for Primary Sclerosing Cholangitis Report:
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis
The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis.
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
Competitive Analysis for Primary Sclerosing Cholangitis
Key players are making innovative developments in Primary Sclerosing Cholangitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.
The key players in this market are Albireo Pharma Inc, Arena Pharmaceuticals Inc, Cadila Healthcare Ltd, Dr. Falk Pharma GmbH, Gilead Sciences Inc, Novartis AG, Tiziana Life Sciences Plc and Virobay Inc
Table of Contents
Global Markets Direct Report Coverage 5
Primary Sclerosing Cholangitis - Overview 6
Primary Sclerosing Cholangitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Primary Sclerosing Cholangitis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development 19
ActiveSite Pharmaceuticals Inc 19
Coherus BioSciences Inc 19
Lupin Ltd 20
Mabion SA 20
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349